“…A recent pilot clinical study shows similar effectiveness of long-term treatment (i.e., 4–6 years) with transcorneal(tco)ACS ( Ota et al, 2018 ). Moreover, tcoACS has also proven to be useful in the treatment of retinitis pigmentosa, wherein recent clinical studies in humans demonstrate both structural and functional improvement ( Schatz et al, 2011 ; Bittner and Seger, 2018 ; Bittner et al, 2018 , however, see Wagner et al, 2017 ). Several other clinical studies demonstrate that tcoACS can improve visual function (i.e., visual acuity and/or visual field) in patients with various retinal diseases, including retinal artery occlusion, traumatic optic neuropathy, non-arteritic ischemic optic neuropathy, and Best vitelliform macular dystrophy (for a review, see Ota et al, 2018 ).…”